CEACAM1 and neoplasm: A global assessment of CEACAM1, PD1, and PD-L1 was conducted on the exported and re-clustered B cells which identified cell populations that expressed these markers in diseased (tumor and PBMC)-associated samples of both treatment-naive and -resistant patients but not healthy donors (Fig. 3b).